MPC1 and glioblastoma: Certainly, MPC-deficient cells are more resistant to radio- and chemotherapy in vitro [129,139,141], and it was reported that patients treated with temozolomide for glioblastoma showed poorer survival when their tumors expressed low levels of MPC1 compared to patients with MPC1-intact tumors [143].